强生(JNJ)
icon
搜索文档
3 Key Earnings Reports to Watch Next Week
ZACKS· 2024-07-13 08:15
The 2024 Q2 earnings season is in full swing, with today’s results from the big banks kicking the period into a higher gear. Another period of positivity is expected, with the S&P 500 expected to post positive earnings growth yet again.And concerning next week’s docket, several reports, including those from Netflix (NFLX) , Taiwan Semiconductor (TSM) , and Johnson & Johnson (JNJ) should be on investors’ radars. Let’s take a closer look at how each stacks up heading into their respective quarterly releases.N ...
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
ZACKS· 2024-07-12 22:21
The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.71 per share, indicating a decline of 3.2% compared to the year-ago period. Analysts forecast revenues of $22.38 billion, representing a decrease of 12.3% year over year.Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...
3 Essential Stocks for Building a Recession-Proof Portfolio
Investor Place· 2024-07-12 18:23
Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk.The stock market has cooled off following its AI-powered surge for the last two years. While most experts have called for a soft economic landing, the looming possibility of a recession next year complicates the investing landscape. Hence, the focus is now more on resilient and operationally efficient companies that can hold their own during economic downturns.These businesses boast robust fundamentals thanks ...
Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality
Seeking Alpha· 2024-07-11 20:40
MEDITERRANEAN/iStock Unreleased via Getty ImagesIntroduction Pharmaceutical and medical devices giant Johnson & Johnson (NYSE:JNJ) will release its second quarter results on Wednesday, July 17 at 8:30 a.m. Eastern Time. While in my last article I previewed the first quarter results and shared my view on the then-announced acquisition of Shockwave Medical, Inc., the topic of this earnings preview focuses on JNJ's earnings quality. Johnson & Johnson is known for its clockwork-like track record, meeting an ...
AI picks 3 must-have dividend stocks for 2024 H2
Finbold· 2024-07-09 21:30
In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024. These companies have built a track record of resilience, consistent performance, and a commitment to rewarding shareholders through reliable dividend distributions.In this line, Finbold turned to OpenAI’s latest and most advanced AI platform, ChatGPT-4o, to gather insights on the must-have dividend stocks for the ...
Johnson & Johnson: Remaining A Buy Despite Remaining Risks
Seeking Alpha· 2024-07-08 14:51
JHVEPhoto In my last article, I called Johnson & Johnson (NYSE:JNJ) (NEOE:JNJ:CA) a very cautious “Buy” but since my last article Johnson & Johnson continued to decline further and the stock lost about 9% in value during the last 10 months. Especially when comparing the performance to the S&P 500 (SPY) which increased 23% in the same timeframe, we have to see Johnson & Johnson rather as a disappointment. Johnson & Johnson is not really declining steeply, but the stock is slowly creeping lower and has re ...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Prnewswire· 2024-07-02 19:30
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone ( ...
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
The Motley Fool· 2024-06-30 17:40
Income-seeking investors can find plenty of opportunities in any market environment. Dividend stocks offer a great way to add cash to your portfolio and help you compound your overall returns with time. Whether you use that dividend money to add to your portfolio or cash it out, these types of stocks can help you diversify the types of businesses you own shares in. When it comes to investing in dividend stocks, you need to make sure the companies you buy have a strong underlying business and balance sheet t ...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Prnewswire· 2024-06-28 23:30
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+ HELSINKI, June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over ...
Is Johnson & Johnson Stock a Buy?
The Motley Fool· 2024-06-27 16:23
Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company. Johnson & Johnson (JNJ -0.25%) is focusing on the next iteration of its business -- one that investors hope creates a lot more growth than in years past. The company spun off its consumer health business last year, and with just two main segments moving forward -- medical devices and innovative medicines -- J&J could be in a good position to accelerate its growth rate. But investors don't ...